BioSpace News Archive

Innovent Biologics, Inc. (“Innovent”, HKEX: 01801), announced that the results of the Phase 2 study in Chinese patients with advanced cholangiocarcinoma were released today at the European Society for Medical Oncology (ESMO) Congress 2021 (E-poster # 50P).

Agenus today presented final results from the Bal/Zal combination study at the European Society for Medical Oncology (ESMO) Virtual Conference 2021 in an abstract titled Balstilimab

Zogenix (NASDAQ: ZGNX) today announced that the compensation committee of the company’s board of directors granted inducement awards to fourteen (14) new employees.

AbCellera (Nasdaq: ABCL) today announced the U.S. Food and Drug Administration (FDA) has expanded the Emergency Use Authorization (EUA) for bamlanivimab (LY-CoV555) 700 mg administered with etesevimab (LY-CoV016) 1400 mg to include post-exposure prophylaxis (PEP) to prevent SARS-CoV-2 infection or symptomatic COVID-19.

Qilian International Holding Group Limited today announced its unaudited financial results for the first six months of fiscal year 2021 ended March 31, 2021.

Novartis today announced positive health-related quality of life (HRQoL) data from its Phase III VISION study evaluating 177Lu-PSMA-617, an investigational targeted radioligand therapy, plus standard of care for metastatic castration-resistant prostate cancer (mCRPC) versus standard of care alone.

Everest Medicines (HKEX 1952.HK, “Everest”) announced today that it has entered into an exclusive licensing agreement with Suzhou Sinovent Pharmaceuticals Co., Ltd. (“Sinovent”) and SinoMab BioScience Limited (stock code: 3681.HK “SinoMab”) to develop, produce and commercialize XNW1011 (referred as “SN1011" by SinoMab), a covalent reversible Bruton’s tyrosine kinase (BTK) inhibitor, globally for the treatment of renal diseases.

Clinical immunoanalyzer is a diagnostic device used to detect specific analytes in blood or in fluids by employing immunoassay processes such as chemiluminescence immunoassay, enzyme linked fluorescent immunoassay, enzyme linked immunosorbent assay, and radioimmunoassay (RIA).

The reports at TMR Research provide qualitative solutions that break the barriers of doubt or uncertainties when the stakeholders plan to expand their growth reach.

Athenex, Inc., a global biopharmaceutical company dedicated to the discovery, development, and commercialization of novel therapies for the treatment of cancer and related conditions, announced the presentation of data from a Phase 1 study to assess the safety, tolerability, and activity of oral paclitaxel and encequidar in combination with pembrolizumab in patients with advanced solid malignancies.